2021 ESC Guidelines on cardiovascular disease prevention in clinical practice

European Heart Journal, Journal Year: 2021, Volume and Issue: 42(34), P. 3227 - 3337

Published: Aug. 30, 2021

The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical judgment, as well determination implementation preventive, diagnostic strategies; however, do override, way whatsoever, individual responsibility make appropriate accurate decisions each patient's condition consultation with that patient and, where necessary, caregiver.Nor exempt from taking full updated competent order manage case light scientifically accepted data pursuant respective ethical professional obligations.It also professional's verify applicable rules regulations relating drugs devices prescription.

Language: Английский

---

2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation

European Heart Journal, Journal Year: 2020, Volume and Issue: 42(14), P. 1289 - 1367

Published: July 10, 2020

A correction has been published: European Heart Journal, ehaa895, https://doi.org/10.1093/eurheartj/ehaa895

Language: Английский

---

2021 ESC/EACTS Guidelines for the management of valvular heart disease

European Heart Journal, Journal Year: 2021, Volume and Issue: 43(7), P. 561 - 632

Published: June 11, 2021

Guidelines •

Language: Английский

---

2020 International Society of Hypertension Global Hypertension Practice Guidelines

Hypertension, Journal Year: 2020, Volume and Issue: 75(6), P. 1334 - 1357

Published: May 6, 2020

Language: Английский

---

KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease

Kidney International, Journal Year: 2024, Volume and Issue: 105(4), P. S117 - S314

Published: March 13, 2024

This article is published as part of a supplement sponsored by Kidney Disease: Improving Global Outcomes (KDIGO). The opinions or views expressed in this are those the authors and do not necessarily reflect recommendations International Society Nephrology Elsevier. Dosages, indications, methods use for products that referred to may their clinical experience be derived from professional literature other sources.

Language: Английский

---

2023 ESC Guidelines for the management of acute coronary syndromes

European Heart Journal, Journal Year: 2023, Volume and Issue: 44(38), P. 3720 - 3826

Published: Aug. 25, 2023

Language: Английский

---

2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)

European Heart Journal, Journal Year: 2022, Volume and Issue: 43(41), P. 4229 - 4361

Published: Aug. 26, 2022

65-74 years, Sex category (female) CIED Cardiac implantable electronic device CML Chronic myeloid leukaemia CMR magnetic resonance COMPASS-CAT Prospective COmparison of Methods for thromboembolic

Language: Английский

---

2023 ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension

Journal of Hypertension, Journal Year: 2023, Volume and Issue: 41(12), P. 1874 - 2071

Published: June 24, 2023

Document Reviewers: Luis Alcocer (Mexico), Christina Antza (Greece), Mustafa Arici (Turkey), Eduardo Barbosa (Brazil), Adel Berbari (Lebanon), Luís Bronze (Portugal), John Chalmers (Australia), Tine De Backer (Belgium), Alejandro de la Sierra (Spain), Kyriakos Dimitriadis Dorota Drozdz (Poland), Béatrice Duly-Bouhanick (France), Brent M. Egan (USA), Serap Erdine Claudio Ferri (Italy), Slavomira Filipova (Slovak Republic), Anthony Heagerty (UK), Michael Hecht Olsen (Denmark), Dagmara Hering Sang Hyun Ihm (South Korea), Uday Jadhav (India), Manolis Kallistratos Kazuomi Kario (Japan), Vasilios Kotsis Adi Leiba (Israel), Patricio López-Jaramillo (Colombia), Hans-Peter Marti (Norway), Terry McCormack Paolo Mulatero Dike B. Ojji (Nigeria), Sungha Park Priit Pauklin (Estonia), Sabine Perl (Austria), Arman Postadzhian (Bulgaria), Aleksander Prejbisz Venkata Ram Ramiro Sanchez (Argentina), Markus Schlaich Alta Schutte Cristina Sekib Sokolovic (Bosnia and Herzegovina), Jonas Spaak (Sweden), Dimitrios Terentes-Printzios Bruno Trimarco Thomas Unger (The Netherlands), Bert-Jan van den Born Anna Vachulova Agostino Virdis Jiguang Wang (China), Ulrich Wenzel (Germany), Paul Whelton Jiri Widimsky (Czech Jacek Wolf Grégoire Wuerzner (Switzerland), Eugene Yang Yuqing Zhang (China).

Language: Английский

---

2020 ESC Guidelines on sports cardiology and exercise in patients with cardiovascular disease

European Heart Journal, Journal Year: 2020, Volume and Issue: 42(1), P. 17 - 96

Published: July 10, 2020

The ESC Guidelines represent the views of and were produced after careful consideration scientific medical knowledge evidence available at time their publication.The is not responsible in event any contradiction, discrepancy and/or ambiguity between other official recommendations or guidelines issued by relevant public health authorities, particular relation to good use healthcare therapeutic strategies.Health professionals are encouraged take fully into account when exercising clinical judgment, as well determination implementation preventive, diagnostic strategies; however, do override, way whatsoever, individual responsibility make appropriate accurate decisions each patient's condition consultation with that patient and, where necessary, caregiver.Nor exempt from taking full updated competent order manage case light scientifically accepted data pursuant respective ethical professional obligations.It also professional's verify applicable rules regulations relating drugs devices prescription.

Language: Английский

---

Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

New England Journal of Medicine, Journal Year: 2020, Volume and Issue: 382(16), P. 1507 - 1519

Published: March 18, 2020

Inclisiran inhibits hepatic synthesis of proprotein convertase subtilisin-kexin type 9. Previous studies suggest that inclisiran might provide sustained reductions in low-density lipoprotein (LDL) cholesterol levels with infrequent dosing.We enrolled patients atherosclerotic cardiovascular disease (ORION-10 trial) and or an risk equivalent (ORION-11 who had elevated LDL despite receiving statin therapy at the maximum tolerated dose. Patients were randomly assigned a 1:1 ratio to receive either (284 mg) placebo, administered by subcutaneous injection on day 1, 90, every 6 months thereafter over period 540 days. The coprimary end points each trial placebo-corrected percentage change level from baseline 510 time-adjusted after 90 up 540.A total 1561 1617 underwent randomization ORION-10 ORION-11 trials, respectively. Mean (±SD) 104.7±38.3 mg per deciliter (2.71±0.99 mmol liter) 105.5±39.1 (2.73±1.01 liter), At 510, reduced 52.3% (95% confidence interval [CI], 48.8 55.7) 49.9% CI, 46.6 53.1) trial, corresponding 53.8% 51.3 56.2) 49.2% 46.8 51.6) (P<0.001 for all comparisons vs. placebo). Adverse events generally similar placebo groups although injection-site adverse more frequent than (2.6% 0.9% 4.7% 0.5% trial); such reactions mild, none severe persistent.Reductions approximately 50% obtained inclisiran, subcutaneously months. More occurred placebo. (Funded Medicines Company; ClinicalTrials.gov numbers, NCT03399370 NCT03400800.).

Language: Английский

---